QPS Holdings, LLC
QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has rapidly expanded from a tiny bioanalysis shop to a full-service CRO with 1100+ employees in the US, Europe, India and Asia. Today, it offers expanded pharmaceutical contract R&D services with special expertise in Pharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine and all Phases of Clinical Development. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. For more information, visit www.qps.com or email [email protected].
QPS is celebrating its 30th anniversary in 2025! Read more from Founder and CEO, Benjamin Chien, in this article.
- Website: https://www.qps.com
- Email: [email protected]
- Telephone: 1 512 350 2827
- Address: Delaware Technology Park, 3 Innovation Way, Newark, DE 19711
Breaking Ground in Cancer Treatment: First T-Cell Therapy Approved for Solid Tumors
Can Repeat Dosing with RNA Medicines Be Curative?
RNAi Breakthrough in Heart Disease Treatment
“Like Day and Night” — CRISPR’s Life-Changing Potential in Sickle Cell Disease
mRNA Delivery by Viral Vectors
Gene Therapy for Alzheimer’s Disease
Oligonucleotide Therapeutics: Drug-Drug Interactions (DDI)
Gene Therapy for Parkinson’s Disease
Oligonucleotide Anti-Drug Antibodies (ADAs)
Going Non-Viral — Rethinking Gene Therapy Delivery
Understanding Therapeutic Oligonucleotides ADME
In Vivo vs. Ex Vivo Gene Therapy
Could the Next Blockbuster Drug be Designed by Artificial Intelligence?
Research Reveals Yellow Crazy Ants’ Intriguing Chimerism
Rare Genetic Mutation Offers Clues for Understanding Alzheimer’s Disease
Wilson Disease: A Rare Genetic Condition with Serious Consequences
Can the Bat Genome Inform Pandemic Prevention?
Can We Reverse Aging by Targeting Old Cells?
Research on Extending Lifespan with Cell Reprogramming Yields “Cautious Optimism”
Experimental mRNA Vaccine Takes a Multivalent Approach to the Flu
Discovery: Pupal Ants Produce Milk for Their Colonies
Attacking KRAS Proteins to Kill Cancer
Reporting Live From the Brain — Tiny Microscope Tracks Activity in Moving Mice
Researchers Find New Hybrid Virus in Lung Cells
New Anti-Amyloid Drug Offers Cognitive Benefit for Patients with AD
Are the New COVID Boosters Better Than the Old Boosters?
Lymphatic Delivery Offers Potential Perks for Kinase Inhibitors and Other Cancer Drugs
It Took Time, But Ionis Made Antisense Therapy Make Sense
How Ancient Wolves Evolved into Mans’s Best Friend
Study Finds Norovirus Could Spread Through Saliva
Could Bear Serum Help the Bedridden?
FDA Sanctions First Interchangeable Biosimilar Sans Switching Study
Research Reveals a Fungi-Cancer Connection, with Potential Diagnostic Implications
How SARS COV2 Spreads Infection So Efficiently: Part 1 The Spike Protein
Clinical Trial Shows in vivo CRISPR CAS9 Therapy Effective Against Rare Disease
Could Giraffes Advance Human Genetic Research?
The SARS COV2 Jump From Bats To Humans And What It Tells Us
Could a New Gap-Free Human Genome Make Personal DNA Sequencing “Routine” Care?
The Potential of a Self-Amplifying mRNA Vaccine Is Heard Loud and Clear
Shedding Light on the Dark Proteome
3D DNA: Imaging and Sequencing Finally Reveal Genomic Structure
New Draft FDA Guidance on ADC Pharmacology
Lilly/Entos Deal Reinforces the Significance of Delivery Mechanisms for Nucleic Acid-Based Therapies
Longhorn Beetles, 200-Year-Old Fish, and How Genetics Drive Genomic Diversity
Cancer Cure? 10-Year Leukemia Remission Reported with Personalized T-Cell Therapy
A New Proteo-Genomic Map Shows How Genes Connect to a Variety of Diseases
Approved: First Drug to Boost Growth in Children With Dwarfism
A Novel Approach to a New mRNA-Based Lyme Disease Vaccine: Tick Saliva
Sign up for QPS Blog Updates!
eBook: Expedited programs for gene and cellular therapies
eBook: ICH M10 Bioanalytical Method Validation
eBook: High-Resolution Mass Spectrometry
eBook: the bioanalytical challenges and considerations of immunogenicity
eBook: Bioanalytical strategies for oligonucleotide assessment
eBook: Toxicology studies – considerations for design and regulatory requirements
eBook: biomarker assay development with mass spectrometry
eBook: Understanding drug-protein binding and ADME studies for DMPK
Innovative new Leukopak facility at QPS: an interview with Polung Yang
How are pharmacology disease state models used for drug development?
The new frontier: the bioanalysis of cell and gene therapies podcast
QPS Taiwan: new facility expansion and the challenges of pharmacology drug-related projects
Technology Digest: LBAs vs chromatographic platforms for oligonucleotide quantification
Ask The Experts: the impact of COVID-19 on the lab
Protein binding determination, QC and acceptance criteria: an interview with Simon Wong
Peek behind the paper: LC–TOF–MS methods to quantify siRNAs
Peek behind the paper: how ADA methodology informs SARS-CoV-2 assay development
Ask the Experts – hybrid LBA/LC–MS
Ask the Experts: oligonucleotide analysis and therapeutics
Brexit or not, the drug research and development landscape has changed
Hybrid LC–MS assays reaching standards for regulatory filings
QPS expands their translational medicine capabilities at flagship facility in Delaware
QPS White Paper – Three lessons to help accelerate pharmaceutical breakthroughs for CNS disorders
International Women’s Day: an interview with Manuela Prokesch
International Women’s Day: an interview with Birgit Hutter-Paier
International Women’s Day: an interview with Stacey Gottschall
Panel discussion: LBA and LC–MS/MS hybrid assays
Panel discussion: bioanalysis for the development and regulatory approval of cell and gene therapies
Panel discussion: developing careers within the bioanalytical field
Panel discussion: new modalities within bioanalysis
Global Expedited Programs for Cell and Gene Therapies
Oligonucleotide Drug Analysis Using Hybridization ELISA
Metabolite Profiling in Human AME Studies for Regulatory Submission
Defining a Full-Service ADME Data Package
The 5S of Hybrid LC MS/MS Methods
Challenges in Regulated Quantitative LC-MS Bioanalysis
3 Attributes of a Great Bioanalysis CRO Partner
The Application of (LC)-ICP-MS in Drug Development
Ligand Binding or Mass Spectrometry That is the Question
Panel discussion: developments in the oligonucleotide field
Panel discussion: FDA guidance, transitioning skills and future hopes for the bio lab
Business of bioanalysis: season two
The changing world of bioanalysis panel discussion
2025
2024
2023
QPS Opens Additional Preclinical Research Facility In Taipei, Taiwan
2022
Lipum has entered a partnership with QPS Netherlands B.V. for its first clinical trial with SOL-116
QPS Holdings LLC Announces a New Director of Neuropharmacology
2021
QPS Supports COVID-19 Vaccine Development In Taiwan
QPS Awarded Five 2021 CRO Leadership Awards
2020
QPS Missouri Projected to Pay $1 Million to Local Participants
QPS Awarded Two 2020 CRO Leadership Awards
QPS Announces Novel Coronavirus/COVID-19 Testing Capability
QPS Forms Partnership with UMCG and G-CURE for Cardiovascular Drug Development
For more information about QPS at each conference, please visit our page.
This is the list of conferences QPS plans to exhibit at in 2025. We hope to see you soon!
- Advanced Therapies Week (Dallas, TX) – January 20-23
- OCT West Coast (Burlingame, CA) – February 11-12
- EIP (Lisbon, Portugal) – February 24-26
- World ADC (London, UK) – March 3-6
- WRIB (New Orleans, LA) – April 7-11
- OCT Europe (Barcelona, Spain) – April 29-30
- AAPS NBC (Boston, MA) – May 4-7
- Delaware BIO (Wilmington, DE) – May 7-11
- ISCT (New Orleans, LA) – May 7-10
- European Congress on Obesity (Malaga, Spain) – May 11-14
- TIDES (San Diego, CA) – May 19-22
- ASCO (Chicago, IL) – May 30 – June 3
- OCT UK & Ireland (London, UK) – June 10-11
- SSF Kansas City (Kansas City, MO) – July 14-17
- ISSX (Chicago, IL) – September 21-24
- OCT Southern California (San Diego, CA) – September 23-24
- NLS Days (Gothenburg, Sweden) – October 13-14
- OCT New England (Boston, MA) – October 15-16
- ESMO (Berlin, Germany) – October 17-21
- AAPS PharmSci 360 (San Francisco, CA) – November 9-12
- OCT DACH and Western Europe (Zurich, Switzerland) – November 12-13
- EBF Open Symposium (Barcelona, Spain) – November 18-20
- OCT Korea (Seoul, South Korea) – December 2-5
 |
Bridging science and safety: exploring toxicology studies and regulatory requirementsIn this podcast episode, Charlene Chen (QPS; Taipei, Taiwan) delves into all things toxicology, discussing the factors that influence species selection, how to mitigate off-target toxicity and how regulatory requirements impact toxicology study design. Charlene also shares some recent successful compounds that have progressed to clinical trial testing, commenting on their status in the drug development pipeline. |
 |
The new frontier: regulatory implications for cell and gene therapiesIn the first episode of The new frontier podcast, we spoke to Executive Director and Global Head of Regulatory Services Kimberley Buytaert-Hoefen about her experience with cell and gene therapy (CGT) approvals and the barriers to getting these important therapeutics to the patient. Kim advises early regulatory interaction and collaboration to improve the success rate of applications and emphasizes the importance of global harmonization of regulatory standards. We discuss key barriers to CGT approvals including manufacturing and immunogenicity and Kim voices her excitement for the newly approved CRISPR-Cas9 technology to treat sickle cell disease. |
 |
The new frontier: using LC–MS/MS for quantitative assays to support gene therapiesIn the third episode of The New Frontier podcast, we’re joined by Daniel Schulz-Jander, Senior Director of Mass spectrometry Bioanalysis at QPS Netherlands (Groningen). Daniel explains how he uses immune-precipitation and immunoaffinity LC–MS/MS techniques for his work relating to macromolecular pharmaceuticals like gene therapies, as well as their benefits and challenges. Daniel also covers bottom-up, middle-down and top-down approaches and their suitability for his work in clinical support versus research and discovery. |
The frontiers of obesity treatment
Tissue distribution data: how to choose the right imaging method
Messenger RNA: design utility and bioanalysis
Therapeutic RNAs: past, present and future
Therapeutic Oligonucleotide Metabolite Identification
Regulatory Considerations in Gene and Cellular Therapy
5 Criteria to Use When Selecting a CRO for a Gene Therapy Study
The Anitbody Drug Conjugate Challenge
Confidently Choose a CRO to Support Your IND Efforts
 |
A FLEXIBLE APPROACH TO BIOANALYSISAt QPS, bioanalysis brings together leading-edge technologies on small molecules, protein biotherapeutics, vaccines and cell & gene therapies, and provides a full range of bioanalytical solutions to support drug development from drug discovery through clinical development. Access the brochure here! |
 |
A FLEXIBLE APPROACH TO BIOMARKERSAt QPS, translational medicine brings together leading-edge technologies and pharmaceutical research & development experience to create a business service unit that works efficiently to advance your drug development program. Access the brochure here! |
 |
A FLEXIBLE APPROACH TO BIOTHERAPEUTICS AND VACCINESAt QPS, translational medicine brings together leading-edge technologies and pharmaceutical research and development experience, working efficiently to advance your custom-built drug development program. Access the brochure here! |
 |
A FLEXIBLE APPROACH TO DMPKQPS provides a dedicated team of senior DMPK scientists to select, design and conduct absorption, distribution, metabolism and excretion (ADME) and quantitative whole body audioradiography (QWBA) studies. Access the brochure here! |
 |
A FLEXIBLE APPROACH TO TOXICOLOGYAt QPS, our commitment is to provide each one of our valued customers with a fast and reliable route to clinical Phase I/II studies. We offer a wide range of toxicity and DMPK studies as well as other preclinical safety tests that are essential for your preclinical drug development programs. Access the brochure here! |
Get to know QPS! Read our blog here
- To contact us please click here
- Tweet us @QPSHoldingsLLC
Service areas and areas of focus:
- Bioanalysis
- Biomarkers & Translational Medicine
- Biotherapeutics
- Cell & Gene Therapy
- Clinical Research Services
- Dermal and Transdermal Research Services
- Drug Metabolism & Pharmacokinetics (DMPK)
- Early Phase Clinical Development
- Genomics
- ICP MS
- IND Package
- Late Phase Clinical Development
- Leukopaks and PBMCs
- Method Development & Method Validation
- Pharmacology
- Small Molecules
- Study Recruitment
- Toxicology
Download the QPS Assay App Here – iTunes
Download the QPS Assay App Here – Android
To find out more about QPS Holdings, LLC, please click here to visit our website